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Abstract
Despite symptom assessment serving as one of the primary aspects of management for atrial
fibrillation, no standardized instrument for documenting symptoms exists. The purpose of this
project is to further assess the utility of the Canadian Cardiovascular Society Severity of Atrial
Fibrillation (CCS-SAF) scale within the subspecialty of electrophysiology at the Minneapolis
Heart Institute. The target population is physicians, nurse practitioners, and physician assistants
within the subspecialty electrophysiology evaluating patients in the clinic setting. Before scale
implementation, dissemination of information regarding the scale occurred through an
educational session and pre-implementation survey. Following an implementation period of six
weeks, a post-implementation survey was completed to identify the value of a symptom severity
scale. Participation in the post-implementation survey was 54%. The CCS-SAF scale improved
communication and assisted with assessing response to therapy; however, utility of the scale for
treatment decisions was equivocal. A significant factor limiting integration of the scale into
documentation was the absence of an automated process. Based on these findings, creation of a
system-wide SmartText is occurring to enhance scale use. With consistent use, the goal is the
scale will permeate not only the subspecialty of electrophysiology but general cardiology,
additional cardiovascular subspecialties, internal medicine, and family practice as well. Through
ongoing use of the scale, there will be less variation in the assessment of atrial fibrillation, and
further data to assess utility in the clinical setting.
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Implementing an Atrial Fibrillation Symptom Severity Scale within the Subspecialty of
Electrophysiology at the Minneapolis Heart Institute
Chronic conditions are increasing in prevalence across the United States, significantly
contributing to morbidity and mortality (Centers for Disease Control and Prevention [CDC],
2018). Atrial fibrillation, the most prevalent arrhythmia encountered in clinical practice (Ha et
al., 2014) and leading cause for arrhythmia-related hospitalizations (Heidt et al., 2016; Sheikh et
al., 2015), is one example of a chronic illness that affects numerous individuals. The aging
population and rise in risk factors such as hypertension and heart disease are some of the major
contributing factors for the increasing prevalence of atrial fibrillation (Fosbol et al., 2013;
Proietti et al., 2017).
As the number of individuals with atrial fibrillation increases, so do costs, morbidity, and
mortality. According to Sheikh et al. (2015), when comparing hospitalization costs for
individuals with and without a history of atrial fibrillation, those with a history of atrial
fibrillation have expenses approximately three times higher than those without this diagnosis.
Expenditures surrounding atrial fibrillation are high, costing the health care system in the United
States nearly six billion dollars annually (CDC, 2017).
More concerning than the financial burden of atrial fibrillation is the increase in
morbidity and mortality. “AF [atrial fibrillation] is independently associated with a two-fold
increased risk of all-cause mortality in women and a 1.5-fold increase in men” (European
Society of Cardiology [ESC], 2016, p. 2899). Across the nation, atrial fibrillation contributes to
approximately 130,000 deaths annually (CDC, 2017). Despite technological advances for the
identification and treatment of atrial fibrillation, death rates linked to atrial fibrillation have been
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rising for the past 20 years (CDC, 2017) and the related morbidity and mortality remain
unacceptably high (Kirchhof et al., 2016).
Problem Formation
Background
Given the increasing prevalence, high costs, morbidity, and mortality associated with
atrial fibrillation, appropriate management is critical (Fosbol et al., 2013). Health care providers
play an integral role in this challenge. When managing atrial fibrillation, a major focus is
associated symptoms. According to Zimmerman et al. (2016), “assessing and measuring
symptoms is the basis for triage, diagnostic testing, and treatment and so is a priority for patients,
clinicians, and researchers” (p. 475). Reducing the symptom burden associated with atrial
fibrillation not only improves quality of life but assists with lowering morbidity and mortality as
well (Heidt et al., 2016).
Despite recommendations from the European Society of Cardiology (2016), American
Heart Association, American College of Cardiology, and Heart Rhythm Society (2014) to assess
symptoms prior to initiation of treatment for atrial fibrillation, consistency is lacking.
Differences exists among both assessment and treatment of atrial fibrillation. “Large variation in
therapeutic approach suggests that there may be a substantial proportion of patients lacking
treatment that can significantly improve quality of life” (Gehi et al., 2017, p. 95). One method to
reduce practice variation is through adoption of quality improvement tools (Gehi et al., 2017).
An example of a quality improvement tool is a disease-specific, symptom severity scale.
Consistent assessment and documentation of symptoms related to atrial fibrillation through use
of a symptom severity scale will provide further clinical data. This information can be utilized to
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reach a collaborative decision regarding the best management strategy based on quality of life,
guideline recommendations, and evidence-based practice.
Not only do disease-specific symptom scales assist with quantifying the impact of atrial
fibrillation (Heidt et al., 2016), they also help identify suboptimal management. In a study by
Freeman et al. (2015), use of a disease-specific, provider-administered symptom scale revealed
61.8% of individuals with atrial fibrillation had symptoms, with 16.5% having severe or
disabling symptoms. Fabritz et al. (2017) noted that despite adequate rate control, approximately
half of the individuals remained symptomatic. In further research by Proietti et al. (2017), 25%
of patients managed in a cardiology clinic were symptomatic at a two year follow up. Given the
high incidence of symptoms associated with atrial fibrillation, there is clear need to enhance
management. One aspect that can assist in this process is consistent application of a diseasespecific symptom severity scale in clinical practice.
Problem Statement
Despite the presence of disease-specific instruments to assess atrial fibrillation severity,
there is no consensus on what scale to use. Without agreement, significant variation in the
inclusion of symptoms will persist. Comprehensive clinical evaluation for all individuals with
atrial fibrillation assists with reducing adverse outcomes (Proietti et al., 2017). By lowering
variability and consistently implementing one disease-specific, provider-administered symptom
severity scale across clinical practice, there will be less variation in assessment and enhanced
management for individuals with atrial fibrillation.
Needs Assessment
The working hypothesis was desire for a disease-specific, provider-administered
symptom severity scale within the subspecialty of electrophysiology at the Minneapolis Heart
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Institute would be high given management of a large number of individuals with a diagnosis of
atrial fibrillation. To further explore this need, creation of a pre-implementation survey took
place. Of the six respondents, 100% reported assessing and documenting symptoms for
individuals with atrial fibrillation (SurveyMonkey, 2017). No respondents indicated use of a
symptom scale, although 100% felt it would be helpful (SurveyMonkey, 2017).
Significance and Contribution to the Literature
Assisting with the development of a treatment plan, assessing response to therapy, and
enhancing communication are a few of the positive impacts consistent use of an atrial fibrillation
severity scale can have. By implementing one disease-specific symptom severity scale, the goal
is to demonstrate these benefits. If data supports the scale assists with the treatment plan,
enhances communication, and helps assess response to therapy, professional organizations can
utilize the information to reach a consensus on what scale to use. Additionally, use of a
symptom severity scale will provide further data for which providers can draw from to determine
whether consultation would be beneficial. Cardiology and electrophysiology input is valuable
for many individuals with atrial fibrillation (Steinberg et al., 2013). A patient-centered
management plan established through specialty clinics, such as electrophysiology, results in a
reduction in hospitalization for individuals with a diagnosis of atrial fibrillation (Tran et al.,
2013).
Significance to the Nursing Profession
The effect of implementing a disease-specific symptom severity scale will be
multifactorial, influencing all members of the care team, with the patient at the center. As the
electrophysiology team at the Minneapolis Heart Institute is an interdisciplinary group, all
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members will contribute to implementation, ongoing utilization, and long-term efficacy of an
atrial fibrillation symptom severity scale.
Nurses play an important role in the successful management of atrial fibrillation through
triage calls and direct patient care. Documentation of symptom severity through a diseasespecific instrument will assist with rapid identification of overall management. This will be
particularly helpful in situations where much of the interaction occurs over the phone. Nurses
within the electrophysiology team play a significant role in this aspect of management.
The interdisciplinary team of physicians, nurse practitioners, physician assistants,
registered nurses, clinical assistants, genetic counselor, and coordinators that form the
electrophysiology group work together with a clear, common goal to improve the quality of life
for those served. This team embodies interdisciplinary collaboration, which Petri (2010)
describes as health care providers from different disciplines working collaboratively to provide
high-quality, patient-centered care. Interdisciplinary teams such as the electrophysiology group
at the Minneapolis Heart Institute strive to attain these goals and data suggests these goals are
becoming a reality. In a study by Fumagalli et al. (2016) it was demonstrated that “…a
multidisciplinary approach to AF [atrial fibrillation] management, covering all aspects of care,
including baseline evaluation, education, therapy, and follow-up could significantly reduce the
incidence of arrhythmia-related hospitalizations and of stroke” (p. 625).
Purpose Statement
Given the lack of consistency in assessing and documenting symptom severity in atrial
fibrillation, there is desire to implement a disease-specific, provider-administered scale.
Although a symptom severity scale will create a standardized method for documentation and put
into context the impact atrial fibrillation has on quality of life (Dorian et al., 2009), utility in
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clinical practice for the electrophysiology group at the Minneapolis Heart Institute for enhancing
treatment decisions, communication, and evaluation remains unclear. The purpose of this project
is to investigate the following question: “For providers within the subspecialty of
electrophysiology at the Minneapolis Heart Institute, what is the impact of a disease-specific
symptom severity scale on communication, treatment, and evaluation in the management of atrial
fibrillation?”
PICO
Physicians, nurse practitioners, and physician assistants within the subspecialty of
electrophysiology at the Minneapolis Heart Institute providing care for patients with a diagnosis
of atrial fibrillation in the clinic setting comprise the population for this project. The intervention
involves implementation of a disease-specific symptom severity scale for patients with a
diagnosis of atrial fibrillation. The comparison is the current practice, which does not include
use of a symptom severity scale. Following application of the scale, a post-implementation
survey will demonstrate the outcome by assessing the subjective impact on communication,
treatment decisions, and evaluation.
There are several objectives and goals for this project, which not only guide
implementation but assist with assessing scale utility as well.
Objectives
-

Select a disease-specific symptom severity scale for implementation by the Summer of
2017.

-

Complete staff education sessions in the Fall of 2017 with subsequent scale
implementation.

IMPLEMENTING AN ATRIAL FIBRILLATION SCALE
-

16

Achieve a 50% completion rate for qualifying patients with documentation of symptoms
associated with atrial fibrillation and severity class during the implementation phase.

-

Analyze the quantitative and qualitative data in the Winter of 2018 to further identify
trends and feasibility of dissemination.

-

Establish recommendations for ongoing use of the symptom severity scale by the Spring
of 2018.

Goals
-

Implement a symptom severity scale within the subspecialty of electrophysiology at the
Minneapolis Heart Institute.

-

Consistent application of a symptom severity scale during initial and follow up visits for
patients with a primary visit diagnosis of atrial fibrillation.

-

Disseminate the scale to general cardiology, additional cardiovascular subspecialties,
internal medicine, and family practice within Allina Health.
Theoretical Framework
Nursing theory plays an important role in clinical practice, research, and providing

direction for a project (Moran, Burson, and Conrad, 2017). Application of the University of
California San Francisco symptom management theory helped to explore the proposed
intervention.
Symptom Management Theory
The symptom management theory is a middle range theory first introduced in 1994 by
faculty at the University of California, San Francisco School of Nursing. This theory “…serves
to guide symptom assessment and treatment in nursing practice and to suggest questions and
hypotheses for nursing research” (Humphreys et al., 2014, p. 141). The symptom management
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theory is applicable to the intervention of a disease-specific symptom severity scale as both the
theory and scale focus on the interplay between symptoms and impact on functional status and
quality of life (Dorian et al., 2009; Humphreys et al., 2014).
As with many theories in nursing, the symptom management theory utilizes a holistic
approach. Surrounding the primary concepts of symptom experience, management, and
outcomes are the larger spheres of person, environment, and health and illness (Humphreys et al.,
2014). A similar comprehensive approach is necessary for application of a symptom severity
scale as not only do symptoms need to be brought to light but so do the possible adverse effects
from treatment and overall functional impact atrial fibrillation is having on the individual.
The symptom management theory will guide one of the goals of the symptom scale;
assessing response to therapy. According to Humphreys et al. (2014), the impact of an
intervention on symptoms is clear and measurable. Additionally, “…improvement in symptoms
can lead to better physical and mental functioning, improved quality of life, shorter hospital stay,
quicker return to work, and greater productivity, all with less cost to the individual, family, and
health care system, or employer” (Humphreys et al., 2014, p. 145). Through enhanced symptom
assessment, the potential for downstream reduction in health care expenditure exists and should
be a focus for all members of society as we strive to be stewards of health equity and social
justice.
Following identification of a nursing theory to help clarify the intervention, a theory to
guide implementation of the symptom severity scale was needed. This process led to
identification of a theory grounded in the discipline of social science.
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Diffusion of Innovation Theory
Rogers’ diffusion of innovation theory explains how, “…over time, an idea or product
gains momentum and diffuses (or spreads) through a specific population or social system”
(Boston University School of Public Health, 2016, para 1). A goal surrounding implementation
of a symptom severity scale within the subspecialty of electrophysiology is that it will become a
standard of practice among the providers in the group. To achieve this goal, the diffusion of
innovation theory outlines the differing adopters and factors impacting the success of
implementation.
The major concept of the diffusion of innovation theory centers around the stages of
adopters and their impact on change. There are five categories of adopters, all of which are
important for effective implementation. Rogers (2003) identifies the following five categories of
adopters: innovators, early adopters, early majority, late majority, and laggards. When adopters
are divided into groups and graphed it reflects that of normal distribution (Rogers, 2003).
Innovators are individuals viewed as risk takers who are willing to venture outside the
status quo (Rogers, 2003). Innovators are important when implementing change as they are the
individuals who embrace the idea, assisting with introduction to others (Rogers, 2003). Early
adopters comprise the next group. They play an essential role in the overall diffusion process as
they are leaders and their acceptance encourages further adoption (Rogers, 2003).
The next group of adopters is the early majority, comprising one of the largest categories
at 34% (Rogers, 2003). This group spends time analyzing the proposal and after contemplation,
embrace the change (Rogers, 2003). Once this group adopts, critical mass occurs. Rogers
(2003) describes critical mass as “…the point at which enough individuals in a system have
adopted an innovation so that the innovation’s further rate of adoption becomes self-sustaining”
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(p. 343). Reaching critical mass is not only important for successful implementation of the scale
among the subspecialty of electrophysiology but further dissemination outside of this group as
well.
Late majority and laggards make up the remaining 50% of adopters (Rogers, 2003). The
late majority are uncertain about a proposal and wait for the majority to adopt before committing
(Rogers, 2003). The laggards make up the final portion. This group of individuals tend to
support the status quo and need further time to process their decision before committing (Rogers,
2003).
In addition to providing framework for scale implementation, the diffusion of innovation
theory serves as a foundation for developing expectations. If one knows in advance that some
individuals will be eager to participate, while others less so, it assists with developing a strategy
to encourage involvement. It also gives the primary investigator realistic expectations for
participation and the change process.
The diffusion of innovation theory also provides a foundation for the factors which will
enhance success. Through demonstration of the advantage, compatibility with practice,
simplicity of use, and outcomes (Rogers, 2003), the likelihood of successful diffusion of the
scale will increase.
Throughout the diffusion of innovation theory is the foundation of communication
(Kaminski, 2011). Lack of communication will stifle the diffusion process. Communicating
with those involved will increase their knowledge and assist with spreading news throughout the
group (Kaminski, 2011). This aspect is incredibly important as it contributes to the overall
efficacy of the diffusion process throughout the differing adopter categories.
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Literature Review
Search Process
Review of CINAHL, PubMed, and the Cochrane Library assisted with identifying atrial
fibrillation symptom severity scales. Search terms were symptoms, symptom management,
symptom severity, symptom severity scale, and quality of life. Following identification of the
search terms, pairing with atrial fibrillation occurred in the advanced search section.
Initially, exploration of publications within the last 10 years took place. However,
following further analysis, publication dates were limited to the past five years in the PubMed
database. This limiting criterion was applied secondary to the high number of similar articles
and large number of results with use of a 10-year publication range.
Application of peer-reviewed, academic journals, English language, and major headings
criteria took place to identify the most relevant data in CINAHL. With exploration of the
PubMed database, limiting criteria applied were free full text, review, and clinical trial. Given
the low number of results, application of limiting criteria in the Cochrane Library database did
not occur.
The initial search process revealed 17 relevant articles. However, after further review,
six were excluded as they did not address the intervention. The 11 articles included in the
appraisal evaluated or employed a disease-specific symptom scale for atrial fibrillation. The
Johns Hopkins Research and Non-Research tools assisted with the appraisal process. For further
detail on the search strategy, refer to Appendix A.
Appraisal
Application of the Johns Hopkins Non-Research Evidence Tool (2013) helped with the
appraisal of the literature review and practice guideline. Evidence level for the literature review

IMPLEMENTING AN ATRIAL FIBRILLATION SCALE

21

by Aliot, Botto, Crijns, and Kirchhof (2014) is V and quality high (A), with expertise, clear
conclusions, and rationale for further exploration of quality of life in individuals with atrial
fibrillation. Evidence level for the clinical practice guideline by the European Society of
Cardiology (2016) is IV and quality high (A) secondary to release by a professional agency and
identification of class and level for recommendations.
For the remainder of the studies, the Johns Hopkins Research Evidence Appraisal Tool
(2013) was the hierarchy applied to clarify evidence level. Following identification of the
evidence level, application of the Critical Appraisal Skills Programme (2017) assisted with
reaching a quality rating. There was one evidence level I study. Although high in evidence, the
randomized controlled trial by Bowyer et al. (2017) has a quality rating of good (B) secondary to
limited internal validity (inadequate number included in the control group and no masking of
participants, researchers, or evaluators).
Evidence level III, non-experimental research, represents the remaining eight articles in
the appraisal. The research by Freeman et al. (2015), Ha et al. (2014), Nazli et al. (2016), and
Wynn et al., (2014) are high quality (A) due to detailed explanation of methods, results, and clear
identification of limitations. Additional advantages of the study by Freeman et al. (2015) and Ha
et al. (2014) are the number of patients and multiple locations. These aspects increase both
transferability and generalizability of findings.
The remaining evidence level III studies are good quality (B). Results from Koci et al.
(2014) have limited transferability as implementation occurred at one center on one patient
population. Chiang et al. (2016) did not include a detailed discussion of the measurement tool,
reducing quality. The study by King et al. (2015) noted, “…patients derive significant symptom
relief following rate control or rhythm control therapy” (p. 690), yet one of the limitations is a
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possible placebo effect. Vermond et al. (2014) thoroughly describe the purpose, methods, and
results in their study. With the post hoc design, however, it is difficult to claim a clear
association between symptom severity in atrial fibrillation and adverse cardiovascular outcomes.
For further detail regarding the individual evidence summary tool for each article, refer to
Appendix B.
Synthesis
Much of the research surrounding symptom scales did not directly focus on the
instrument but rather used a scale to assess response to interventions or quantify the impact atrial
fibrillation has on an individual’s quality of life. Both generic and disease-specific scales were
employed. Aliot et al. (2014) note the German Competence Network on Atrial Fibrillation and
the European Heart Rhythm Association “recommend the design, validation, and further use of
AF-specific instruments to assess AF-related QoL [quality of life], particularly when
improvement of symptoms and QoL are the desired primary outcomes” (p. 788).
There is little data to support use of one disease-specific scale over another. Two of the
more prevalent instruments, the Canadian Cardiovascular Society Severity of Atrial Fibrillation
(CCS-SAF) scale and the European Heart Rhythm Association (EHRA) classification are
recommended for clinical use by their respective professional organizations, the Canadian
Cardiovascular Society and the European Society of Cardiology (Ivers & Dorian, 2014; ESC,
2016). Both of these instruments use a numeric scale for classification and are provideradministered. The CCS-SAF scale uses a 0-4 rating, with class 0 being no symptoms related to
atrial fibrillation and class 4 representing severe effect on quality of life from atrial fibrillation
symptoms (Dorian et al., 2009). The EHRA classification rates symptoms on a 1-4 scale, with 1
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representing no symptoms from atrial fibrillation and 4 being disabling symptoms secondary to
atrial fibrillation (ESC, 2016).
In their 2015 research, Freeman et al. assess symptom severity and quality of life for
individuals with a diagnosis of atrial fibrillation. For this analysis, the EHRA classification scale
quantifies symptom severity. The EHRA provides a means for clearly demonstrating the high
percentage (61.8%) of individuals with atrial fibrillation who remain symptomatic (Freeman et
al., 2015). Additionally, for this study, values from the EHRA were compared to the valid,
reliable, and responsive patient completed questionnaire on quality of life, the Atrial Fibrillation
Effect on Quality-of-Life (AFEQT) (Freeman et al., 2015; Zimmerman et al., 2016). Following
analysis, a higher EHRA classification score correlated with lower scores on the AFEQT
questionnaire (Freeman et al., 2015). This finding indicates that not only does the EHRA scale
assist with evaluating symptom severity but quality of life for patients as well (Freeman et al.,
2015).
As use of the EHRA classification scale increased, there was desire to enhance the ability
for the scale to discern a clear difference between mild to moderate symptoms (Wynn et al.,
2014). To further address this, Wynn et al. (2014) proposed a modification to the scale by
dividing class 2 into 2a and 2b. Through further evaluation, there was a significant difference in
level of impact of symptoms (Wynn et al., 2014). Given this, proposal of a modified version of
the EHRA (mEHRA) ensued. The AFEQT was again utilized for comparison to achieve
validity. Following review of the data, a clear trend toward lower quality of life scores
correlated with higher mEHRA classification (Wynn et al., 2014). Subsequently, the European
Society of Cardiology adopted the modified version as the preferred scale for use.
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The remaining articles employing a disease-specific instrument focus on the CCS-SAF
scale. Ha et al. (2014), in their observational cohort sub-study, assess quality of life for patients
with atrial fibrillation when pursuing a rate or rhythm control strategy. Patients complete the
disease-specific, University of Toronto Atrial Fibrillation Severity Scale (AFSS). Comparison
between the results of the AFSS and the CCS-SAF scale then took place, demonstrating the
utility of the CCS-SAF scale as a standardized measure (Ha et al., 2014). As the CCS-SAF class
increases, the AFSS score also rises, demonstrating a linear correlation (Ha et al., 2014).
In the 2015 study completed by King et al., the CCS-SAF scale quantified symptom
severity for patients with minimally symptomatic atrial fibrillation. Following evaluation, even
patients with a perception of low symptom burden benefit from further treatment as the true
extent of their symptoms were more clearly demonstrated following application of the CCS-SAF
scale (King et al., 2015). The CCS-SAF scale can serve as a useful tool for identifying
previously asymptomatic individuals (King et al., 2015), particularly those of advanced age, as
they often place less emphasis on their symptoms (Heidt et al., 2016).
Nazli et al. (2016) utilize both the EHRA classification and CCS-SAF scale in their
study. The CCS-SAF served to quantify the functional impact of symptoms related to atrial
fibrillation and the effects on quality of life (Nazli et al., 2016). Application of the EHRA
classification assisted with identifying the functional consequences of atrial fibrillation (Nazli et
al., 2016). Both scales helped with the conclusions of the study, which indicated that patients
with atrial fibrillation have a high symptom burden as well as impaired quality of life,
particularly those with paroxysmal atrial fibrillation (Nazli et al., 2016).
Although non-research has a lower evidence level on the Johns Hopkins Non-Research
Tool (2013), the clinical practice guideline by the European Society of Cardiology and the
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literature review by Aliot et al. (2014) assisted with further exploration of the topic of interest.
The European Society of Cardiology recommends use of the mEHRA classification scale when
assessing patients with atrial fibrillation with a Class I, Level C recommendation. The mEHRA
classification scale can “…guide symptom-orientated treatment decisions” and allow for longterm monitoring (ESC, 2016, p. 2907).
In the literature review by Aliot et al. (2014), evaluation of both generic and diseasespecific scales for assessing quality of life occurred. Although the future role for diseasespecific instruments such as the CCS-SAF scale and EHRA classification are unclear, both
demonstrate utility for assessing the impact of symptoms and selecting treatments for individuals
with atrial fibrillation (Aliot et al., 2014).
Evidence to Support Intervention
Consensus does not exist across the professional organizations on which provideradministered symptom severity scale to employ when assessing individuals with atrial
fibrillation. Of the articles included in the literature review, only the study by Nazli et al. (2016)
includes both the CCS-SAF scale and EHRA classification. Despite inclusion of both, there was
no comparison between utility in clinical practice.
Use of the CCS-SAF scale occurred in the evidence level III, high quality research by Ha
et al. (2014) and the evidence level III, good quality research by King et al. (2015). Use of the
EHRA/mEHRA took place in the evidence level III, high quality studies completed by Wynn et
al. (2014) and Freeman et al. (2015). The EHRA/mEHRA was validated through comparison to
the AFEQT, which is one of the few scales with not only validity and reliability but
responsiveness as well (Zimmerman et al., 2016). Given this data, the decision was made to
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implement the mEHRA classification scale within the subspecialty of electrophysiology at the
Minneapolis Heart Institute.
Shortly after identifying the desired scale, a research study, which included one of the
team members in the electrophysiology group, was using an alternative disease-specific,
provider-administered severity scale. The focus of the study was to evaluate the safety and
efficacy of a specific catheter for patients with symptomatic, persistent atrial fibrillation
(Minneapolis Heart Institute Foundation®, 2017a). The relevance of this research on the
proposed intervention was use of the CCS-SAF scale to document symptom severity for patients.
Following further consideration, the decision was made to implement the CCS-SAF scale rather
than the mEHRA classification. Given identification of a specific instrument, a focused
literature review on the CCS-SAF scale ensued.
Focused Literature Review
Search Process
Exploration of the PubMed database occurred for further research on the validity and
utility of the CCS-SAF scale. CINAHL was briefly evaluated with no new relevant articles
identified. Search terms included: symptom scale AND atrial fibrillation, Canadian
Cardiovascular Society AND atrial fibrillation, Canadian Cardiovascular Society AND severity
of atrial fibrillation, and symptom instrument AND cardiovascular. There were minimal
restrictions given the specificity of the searches. One additional search for the most up to date
information following the initial literature review performed in the spring of 2017 occurred in the
winter of 2018. This search involved the broad search terms symptoms AND atrial fibrillation.
Restrictions included review, date range from 2016-2017, and free full-text secondary to the
expansive nature of the search.
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Initial evaluation revealed 13 articles. After analysis of the abstracts, four articles met
relevant criteria. The Johns Hopkins Research and Non-Research tools assisted with the
appraisal process. For further detail on the focused search strategy, refer to Appendix C.
Synthesis
The CCS-SAF scale was first proposed in the consensus statement released by Dorian et
al. in 2006. Rationale for the creation and use of the scale was to quantify symptoms related to
atrial fibrillation in a standardized fashion, which could ultimately improve patient care through
facilitating treatment decisions and enhancing communication among the health care team
(Dorian et al., 2006).
The 2009 research article by Dorian et al. validated the CCS-SAF scale. In this study,
correlation existed between the CCS-SAF scale, the generic 36-Item Short Form Health Survey
(SF-36), and disease-specific AFSS. There was an inverse association between the CCS-SAF
and SF-36 and a parallel relationship with the AFSS (Dorian et al., 2009). In addition to
assessing symptom severity, the CCS-SAF scale places into context the impact treatments have
on quality life and is not exclusive to arrhythmia episodes (Dorian et al., 2009).
The literature review by Heidt et al. (2016) addressed the utility of the CCS-SAF in
clinical practice, noting similar findings as to those addressed in the study by Dorian et al.
(2009). Discussion of the mEHRA also took place, but comparison between the two scales did
not occur. Heidt et al. (2016) speculate “…the EHRA, mEHRA, and CCS-SAF scales will
become commonplace in clinical practice” (p. 86).
Zimmerman et al. (2016), in their literature review, note the CCS-SAF incorporates
multiple symptoms, is multi-dimensional, specific, and demonstrates validity. The CCS-SAF
measures symptoms attributed to and associated with atrial fibrillation in addition to therapies
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with their possible consequences, helping to capture all components of the condition (Dorain et
al., 2009; Zimmerman et al., 2016). Some of the limitations of the scale are lack of reliability
given the subjective nature of the scale (provider-administered) and lack of responsiveness
(Zimmerman et al., 2016).
To reduce confusion for this project, the decision was made to move forward with
implementation of the CCS-SAF. Logistically, having two scales would further impair
successful implementation. Following further review, the CCS-SAF was the best option for
implementation among the group as it is valid, easy to apply, captures all aspects of atrial
fibrillation, and is not exclusive to arrhythmia episodes (Dorian et al., 2006; Dorian et al., 2009;
Heidt et al., 2016; Zimmerman et al., 2016).
One constant in both the initial and focused literature review is the lack of data
comparing scales in an attempt to demonstrate superiority. Although the 2014 practice
guidelines from the American Heart Association, American College of Cardiology, and Heart
Rhythm Society recommend assessing symptoms associated with atrial fibrillation during initial
and subsequent evaluation, no scale is endorsed. For further detail on the individual evidence
summary tool, refer to Appendix D.
Project Implementation
The intervention for this project is implementation of the CCS-SAF scale within the
subspecialty of electrophysiology at the Minneapolis Heart Institute. Following evaluation of the
data, the objective is to answer the following question, “For providers within the subspecialty of
electrophysiology at the Minneapolis Heart Institute, what is the impact of a disease-specific
symptom severity scale on communication, treatment, and evaluation in the management of atrial
fibrillation?”
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Stakeholders
Stakeholders for implementation of an atrial fibrillation symptom scale within the
subspecialty of electrophysiology include: physicians, nurse practitioners, physician assistants,
registered nurses, clinical assistants, clinic coordinators, clinic managers, and individuals
evaluated within the clinic with a diagnosis of atrial fibrillation. Pending results for this group,
stakeholders may broaden to include internal medicine and primary care providers within Allina
Health, organizational leaders, and patients served through the Allina Health System with a
diagnosis of atrial fibrillation.
Design
The CCS-SAF is a disease-specific, provider-administered scale for assessing symptom
severity in atrial fibrillation first introduced in 2006 by Dorian et al. Prior to moving forward
with the project, email correspondence with Dr. Paul Dorian verified permission to use the scale
within the clinic (refer to Appendix E for scale criteria and example). Exploration online
revealed a modified version of the CCS-SAF scale from the American College of Cardiology
Foundation (2012). This form is on one page and thus served as a guide for the project as it
enhanced simplicity. Before introducing the modified version, email communication with
American College of Cardiology occurred to gain permission for clinic use (refer to Appendix F
for example).
Implementation of the CCS-SAF scale is a quality improvement project, for which the
plan, do, study, act (PDSA) cycles serve as the design method. This approach is often
implemented on a small scale with further application following analysis of findings (Chapman
& Larson, 2016). As the initial focus is on one group within the Minneapolis Heart Institute, the
objective is to evaluate the outcomes and act on the third goal, dissemination of the scale.
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Release of an information sheet regarding further detail of the project (Appendix G) and
the pre-implementation survey (Appendix H) transpired in November of 2017 following
verification from the Allina Health and St. Catherine University Institutional Review Boards on
quality improvement status of the project. Two education sessions on different dates to further
discuss the project purpose, goals, and objectives occurred. For those unable to attend a session,
a voiceover PowerPoint was available through email. The presentation was available for
physicians, nurse practitioners, physician assistants, registered nurses, clinical assistants, and
schedule coordinators wishing to become familiar with the CCS-SAF scale. The coordinators
were encouraged to include the letters CCS-SAF in the notes section on the schedule for
individuals with a diagnosis of atrial fibrillation. To serve as a remainder during clinic visits,
paper forms of the modified CCS-SAF scale created by the American College of Cardiology
Foundation (2012) were made available. Additionally, all potential participants had access to a
dot phrase in the electronic health record created to further assist with documentation. A
recommendation by the primary investigator was to include the symptoms associated with atrial
fibrillation and the CCS-SAF class in the physical exam section of the progress note. The
implementation period for application of the CCS-SAF scale occurred from December 18, 2017,
through January 26, 2018. Following this period, a post-implementation, online survey was sent
to participants.
Population
Physicians, nurse practitioners, and physician assistants within the electrophysiology
group providing care to patients in the clinic setting with a diagnosis of atrial fibrillation
comprised the population for the project. This group is composed of nine physicians, four nurse
practitioners, and two physician assistants. Thirteen possible participants were available
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following exclusion of the primary investigator and one nurse practitioner not involved with
clinic evaluation. Use of the scale was encouraged for all atrial fibrillation definitions noted in
the 2014 American Heart Association, American College of Cardiology, and Heart Rhythm
Society practice guideline (paroxysmal, persistent, long-standing persistent, and permanent).
There are a number of reasons why the providers within the subspecialty of
electrophysiology at the Minneapolis Heart Institute serve as the focus population for scale
implementation. Not only are there a large number of individuals with atrial fibrillation
evaluated on a weekly basis but additionally The Minneapolis Heart Institute has a partnership
with the Minneapolis Heart Institute Foundation. Collaboration between the Minneapolis Heart
Institute and Minneapolis Heart Institute Foundation assists with translating research into
practice (Minneapolis Heart Institute Foundation®, 2017b). Given this partnership, research
and innovation are highly valued and encouraged, making it an ideal organization and group for
project implementation.
Data Collection
An online survey, both pre and post-implementation, served as the data collection tool for
evaluating the need and utility of the CCS-SAF scale. The pre-implementation survey was open
from November 27, 2017, through December 7, 2017, and the post-implementation survey
January 30, 2018, through February 7, 2018. To further assess overall use of the scale during the
implementation phase, the primary investigator performed a review of the clinic schedule for all
providers within the group and assessed charts for use of the CCS-SAF scale following closure
of the post-implementation survey.
Ethical Considerations
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On September 13, 2017, application to the Allina Health Institutional Review Board
occurred, with verification of quality improvement project on November 16, 2017. The St.
Catherine University Institutional Board agreed with the classification of quality improvement
project on November 19, 2017.
With use of the CCS-SAF scale, there is concern for variability in scoring due to the
subjective nature of the class rating. This lack of inter-rater reliability may result in variation
between provider ratings. A higher score indicates severe impact on quality of life (Dorian et al.,
2009) and aggressive treatment options, which subsequently have a higher risk for complication,
may ensue. Although this concern can not be fully mitigated given the subjective nature of the
scale, the potential benefits of use are felt to outweigh the risks. Furthermore, the modified scale
provided by the American College of Cardiology Foundation (2012) has clear definitions for
qualifying criteria for each classification.
Societal value for implementation of the CCS-SAF scale includes assessing and
documenting symptom severity for all individuals with a diagnosis of atrial fibrillation, which is
a cornerstone for management (Koci et al., 2014). Symptom severity not only gives insight into
the impact atrial fibrillation is having on quality of life but also assists with capturing
“meaningful changes in a patient’s health status over time and more specifically after treatment
interventions” (Koci et al., 2014, p. 261). Research indicates aspects other than symptoms,
quality of life, clinical impact, and patient preference drive decisions regarding the management
of atrial fibrillation (Gehi et al., 2017). Factors that often determine whether a rhythm strategy is
pursued include evaluation by an electrophysiologist, private insurance coverage, and race (Gehi
et al., 2017). This deviation from guideline recommendations demonstrates an opportunity for
decreasing variation in care and enhancing health care equity. Although achieving health equity
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requires numerous system-level changes, consistent implementation of a standardized symptom
severity instrument such as the CCS-SAF scale represents one step in this direction.
Evaluation
Following implementation of the CCS-SAF scale and closure of the post-implementation
survey, data analysis took place. Data consisted of both quantitative and qualitative responses.
Of the 13 qualifying providers, seven completed the post-implementation survey in its entirety.
One survey was partially complete and excluded from the analysis. Based on the survey results,
the CCS-SAF scale did not clearly assist with the treatment plan but did help with enhancing
communication and assessing response to therapy (SurveyMonkey, 2018). It was easy to use,
and 57% of the respondents reported they would continue to use it (SurveyMonkey, 2018).
The qualitative, open-ended questions provided insight regarding the limitations of the
scale. A theme identified from the respondents, with approximately 67% noting this, was the
absence of an automated method for scale integration into the electronic health record
(SurveyMonkey, 2018). One individual noted, “I think it’s a great idea to have a common way
to assess symptoms. The scale is fairly easy to use. The toughest part is just remembering to do
it” (SurveyMonkey, 2018, Q8, #4). Another respondent indicated time as a barrier “…[the scale]
would be more meaningful after longer follow-up periods (eg to assess trend in CCS-SAF scale
after multiple follow-up visits/interventions)” (SurveyMonkey, 2018, Q8, #3). For all postimplementation survey questions and results, refer to Appendix I.
To further assess participation rate, a chart review for all patient visits during the
implementation period of December 18, 2017 through January 26, 2018 took place. Thirteen
providers within the subspecialty of electrophysiology were included, covering four clinic
locations. Inclusion for chart review comprised primary visit diagnosis of atrial fibrillation,
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CCS-SAF in the notes section, and all individuals with an unclear primary visit diagnosis. Of the
clinic visits evaluated in the specified time frame, 249 patients met criteria for completion of the
CCS-SAF scale. Following full review, documentation of the symptoms associated with atrial
fibrillation and subsequent CCS-SAF scale classification occurred for 23 of the qualifying
patients. The overall completion rate was 9.2% of the qualifying individuals, failing to meet the
pre-implementation objective of a 50% compliance rate. For further detail on the chart analysis,
refer to Appendix J.
Given the low participation rate, the overall utility of the CCS-SAF scale within the
electrophysiology group at the Minneapolis Heart Institute remains unclear. Based on the
information from the survey respondents, the scale did assist with communication and assessing
response to therapy. A clear trend from the open-ended questions is the importance of an
automated method for assessing and documenting symptoms and the CCS-SAF class for
individuals with atrial fibrillation in the electronic health record.
Limitations
A significant limitation of this project includes an unknown number of participating
providers. Consent was assumed if a provider completed the pre-implementation survey. As
participation was 50%, it is not clear whether the survey was not completed by the remaining
individuals due to desire not to participate or for other reasons. No clear method for providers to
opt-out was available. The number of patients qualifying for use of the CCS-SAF scale,
therefore, may have been less if the provider was not participating yet the data analysis included
patients from their schedule. A way to remedy this issue moving forward is to have a clear optout option on the pre-implementation survey.
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The time of year implementation occurred was another limitation for this project. The
initial target date for scale implementation was October 2017. However, secondary to
unforeseen delays, implementation did not take place until December 18, 2017. This time of
year presented a number of barriers. One of the most significant being there were no clinic visits
the week of December 25, 2017, through December 29, 2017. Additionally, every qualifying
provider was on vacation at some point throughout the implementation phase, impacting the
ability to apply the scale on a consistent basis.
Not only was the time of year implementation took place a limitation, but so was the
duration of implementation. Of the individuals for which the scale was completed, 16 occurred
in the last three weeks of implementation. Based on this information, use of the scale was on the
rise. Given the limited length of time for project implementation, however, further progress
toward achieving critical mass ceased. Given the limited frequency of visits within the
subspecialty of electrophysiology, an implementation period of at least one year would provide
more useful data for further analysis of scale utility.
To assist with implementation, CCS-SAF was added to the notes section on the daily
schedule prior to the visit. This schedule is available for all providers in the electronic health
record. During the chart review process, CCS-SAF was not included in the notes section on a
consistent basis until January 5, 2018. This was another limitation as no qualifying patients had
the scale added during six of the seven clinic days before inclusion of CCS-SAF in the notes
section.
An additional limitation was the low use of the dot phrase created by the primary
investigator. Creation of a dot phrase (.CCSSAF) occurred prior to scale implementation to
assist with use. However, upon evaluation of the open-ended questions, it appears that many of
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the providers were unaware of this option. Furthermore, during the chart review process, only
one of the 13 providers utilized the dot phrase. This highlights the importance of ongoing
communication throughout the change process and ensuring individuals have a clear
understanding of the available tools.
Discussion
When analyzing the data following implementation of the CCS-SAF scale within the
subspecialty of electrophysiology, it is hard not to question whether symptom severity scales are
worth the effort. It is difficult to see the possible utility when results of a small-scale project
reveal limited involvement. When discouraging thoughts begin to arise, it is important to
remember the purpose. For this project, the aim is to increase symptom identification for those
afflicted with atrial fibrillation. Research consistently demonstrates an opportunity for
enhancing management in atrial fibrillation with upwards of 50% of individuals remaining
symptomatic (Freeman et al., 2015; Fabritz et al., 2016). With review of the postimplementation open-ended questions, the following statement brought the question of utility to
light, “more guidelines [are] needed to connect scale with pathophysiology of disease”
(SurveyMonkey, 2018, Q8, #1). Without clear demonstration of utility, ongoing use of the sale
appears ineffective. However, without consistent implementation, the true clinical value can not
be assessed.
One of the largest barriers at this time is the lack of consensus on what scale to use. The
European Society of Cardiology and Canadian Cardiovascular Society both recommend use of
their respective scales when assessing individuals with atrial fibrillation (ESC, 2016; Ivers &
Dorian, 2014). To further address the lack of consensus, Koci et al. (2014) designed a new atrial
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fibrillation classification scheme as there is a “…pressing need for a validated tool to assess AFspecific patient-reported outcome” (p. 260).
One of the three aims, providing better care for the individual, and two of the six
priorities, enhancing communication and promoting treatment of cardiovascular disease,
identified by the Centers for Medicare and Medicaid Services (2016) are all potentially
addressed with use of the CCS-SAF scale. Two of the primary objectives of the scale are to
assist with treatment decisions and communication (Dorian et al., 2006). Data from this project
indicates a positive impact on these aspects, with 71% of respondents noting enhanced
communication and 57% of respondents reporting assistance with assessing treatment response
(SurveyMonkey, 2018).
Another important aspect of health care is reimbursement. With an ever-growing focus
on value-based programs, outcomes and patient-experience play a crucial role in financial
compensation. Although all provider and patient completed symptom scales possess a subjective
component, having a semi-quantitative value such as that provided by the CCS-SAF scale will
assist with demonstrating outcomes. Furthermore, if professional organizations in the United
States follow that of the European Society of Cardiology and Canadian Cardiovascular Society,
use of a scale will be an aspect of guideline-recommended practice.
Recommendations
Although a majority of the providers anticipated benefit from scale use, participation was
low, limiting the ability to assess overall utility. One of the biggest aspects limiting ease of scale
implementation was lack of an automated format such as SmartText. SmartText are templates
that “…insert a pre-created block of text to facilitate documentation of a note by quickly adding
appropriate information” (Health Information Management, 2012, section 4). Additionally,
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SmartText allow for incorporation of wildcards, SmartLists, and SmartLinks (Health Information
Management, 2012). Furthermore, SmartText provide opportunity for data analysis as tracking
of the entries can occur.
Due to lack of automation in the documentation process, the next step to further assess
utility of the CCS-SAF scale is through creation of an Allina Health system-wide SmartText.
Development of a SmartText did not occur at the onset of the project for two primary reasons;
one being the unclear benefit of the scale and the other the length of time it takes to implement a
system-wide SmartText, which can range from several months up to a year. Although definite
conclusions from the first cycle of the project cannot be made, 57% of the respondents indicated
they would continue to use the scale (SurveyMonkey, 2018).
With creation of a CCS-SAF SmartText, the objective is to enhance integration of the
scale into clinical practice. Through consistent use, the goal is to achieve critical mass over time
within the electrophysiology group. With ongoing use, general cardiology, additional
cardiovascular subspecialties, internal medicine, and family practice will become more familiar
with the scale and if desired, will be able to easily integrate it for patients they care for with a
diagnosis of atrial fibrillation. Having this instrument readily available will allow for
longitudinal monitoring and may also serve as a resource for referral to cardiology and
electrophysiology.
In an era of technology, it is difficult to see the utility of a simple symptom severity scale.
Applicability of symptom scales, however, should not be overlooked. Likened to the New York
Heart Association (NYHA) Functional Classification, atrial fibrillation severity scales may prove
to have similar benefits going forward. The NYHA Functional Classification is a powerful
predictor of mortality for both systolic and diastolic heart failure (Ahmed, Aronow, & Fleg,
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2006; Goode, Nabb, Cleland, & Clark, 2008). Additionally, it has been around for many years,
with the most recent update occurring in 1994, which was the 9th edition (American Heart
Association, 2017). Although patient completed scales are important, data demonstrates the
NYHA Functional Classification given by the providers “…relates more strongly to survival and
severity of left ventricular systolic dysfunction [than patient-reported NYHA Functional
Classification], suggesting…the NYHA classification may have become a ‘heart failure severity
score’” (Goode et al., 2008). Given the provider-administered nature of the CCS-SAF scale, the
utility for correlating the classification with not only atrial fibrillation symptom severity but
morality may exist. The only way to further explore the long-term utility of this scale is through
consistent implementation across not only the subspecialty of electrophysiology but all practices
who care for individuals with a diagnosis of atrial fibrillation.
Even if future research fails to demonstrate a correlation with the CCS-SAF scale and
mortality, it will provide a method for ensuring similar assessment criteria for all patients with
atrial fibrillation, regardless of treating provider specialty or clinic location. Gehi et al. (2017)
note significant practice variation regarding rhythm control management for atrial fibrillation,
suggesting that factors other than patient symptoms and preferences are guiding treatment
decisions. Although the CCS-SAF scale does not provide recommendations for which treatment
strategy to pursue for atrial fibrillation, it does provide a baseline. If a patient is persistently
falling into class 3 or 4 on the scale (moderate to severe impact on quality of life), this may
prompt a change in the management approach or result in referral to cardiology or
electrophysiology.
Future research directly comparing the available provider-administered scales is needed.
This will help not only demonstrate possible advantages one has over another but will assist with
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standardizing the language for symptom severity in atrial fibrillation as well. For this project,
the mEHRA classification was the original choice for scale implementation based on review of
the literature. However, given use of the CCS-SAF scale in a research study occurring at the
same time through the Minneapolis Heart Institute Foundation, the CCS-SAF became the
preferred scale. Upon further review, the CCS-SAF scale was a better fit for a number of
reasons, including ease of use, inclusion of all aspects of atrial fibrillation, and application
outside arrhythmia episodes (Dorian et al., 2006; Dorian et al., 2009; Heidt et al., 2016;
Zimmerman et al., 2016). Although the CCS-SAF fit well for the first cycle of this project,
further research and collaboration between the professional organizations are necessary to
compare the available scales and reach consensus.
Future Implications
As the age of individuals rises across the United States, so does the prevalence of chronic
conditions such as atrial fibrillation (European Society of Cardiology, 2016). Atrial fibrillation
is the most common arrhythmia encountered in clinical practice (Ha et al., 2014) and
independently increases morbidity and mortality in both women and men (European Society of
Cardiology, 2016). Given this data, adequate management is imperative.
Essential aspects in the management of atrial fibrillation include reducing symptom
burden and enhancing consistency across practice. The CCS-SAF scale serves as an example of
a quality improvement tool providers can utilize to address these factors. With a reduction in
associated symptoms, quality of life for those affected with atrial fibrillation will improve and
with less practice variation, we can make further strides toward achieving health equity.
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Appendix A
Search Strategy Table
Data Base
Search
1. CINAHL

Key Words

Restrictions

# articles
identified
8

# articles
relevant
1

Symptom management
AND atrial fibrillation (11)

Publications since 2007 (9); peer
reviewed (8); academic journals (8)

2. CINAHL

Symptom severity AND
atrial fibrillation (48)

3. CINAHL

Symptom severity scale
AND atrial fibrillation (4)
Quality of life AND atrial
fibrillation (643)

Publications since 2007 (29); peer
reviewed (26); academic journals
(26)
None

26

5

4

1

51

3

23

2

25

1

9

2

56

1

31

10. Cochrane
Library
11. Cochrane
Library
12. Cochrane
Library

Publications since 2007 (474); peer
reviewed (460); academic journals
(436); English language (434);
major heading- atrial fibrillation
(316); major heading- quality of life
(97); publications since 2012 (51)
Symptom management
Publication dates- within 5 years
AND atrial fibrillation (178) (75); free full text (23)
Symptom severity AND
Publication dates- within 5 years
atrial fibrillation (163)
(67); free full text (25)
Symptom severity scale
Publication dates- within 5 years
AND atrial fibrillation (55) (23); free full text (9)
Quality of life AND atrial
Publication dates- within 5 years
fibrillation (1,588)
(637); free full text (246); review
(56)
Quality of life AND atrial
Publication dates- within 5 years
fibrillation (1,588)
(637); free full text (246); clinical
trial (31)
Symptom management and None
atrial fibrillation (3)
Symptom severity and atrial None
fibrillation (2)
Symptom severity scale and None
atrial fibrillation (24)

3

0 (no
new
articles)
0

2

0

24

1 new

13. Cochrane
Library

Quality of life and atrial
fibrillation (11)

11

0 (no
new
articles)

4. CINAHL

5. PubMed
6. PubMed
7. PubMed
8. PubMed
9. PubMed

None
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Appendix B
Individual Evidence Summary Tool
EBP Question: What are the Current atrial fibrillation disease-specific symptom severity
assessment scales in use?

Article
#

Author &
Date

1

Bowyer et
al., 2017

Article
#

Author
& Date

Sample,
Sample Size &
Setting
Research,
- Men (65.9%)
randomized and women with
controlled
paroxysmal and
trial
non-paroxysmal
atrial fibrillation
(69%, 31%)
with an average
age of 62.1
- 19 individuals
in the control
group and 22 in
the intervention
for a total of 41
- Setting:
Medical center
in Australia
Evidence
Type

Evidence
Type

Sample, Sample
Size & Setting

Study findings that
help answer the EBP
question
- Short Form 36 (SF-36)
utilized for quality of
life
- Symptoms measured
through use of the AF
Symptom Checklist,
Frequency, and Severity
scale
- Based on SF-36 and
AF Symptom Checklist,
Frequency, and Severity
scores, the nurse led
educational intervention
at the time of ablation,
prior to discharge, and
two weeks, one month,
and three months post
procedure had improved
quality of life scores and
reduced symptoms
severity

Study findings that
help answer the EBP
question

Limitations
- Sample
needed for
each group
identified as
20, yet control
group
contained 19
- Limited
generalizability
as individuals
were selected
from one site
- Some AF
symptoms
were nonspecific
(trouble
concentrating,
poor appetite,
nausea,
difficulty
sleeping)

Limitations

Evidence
Level &
Quality
Evidence
Level I;
Good
Quality
(B)

Evidence
Level &
Quality
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Ha et al.,
2014

Article
#

Author &
Date

3

Freeman et
al., 2015

Research,
nonexperimental;
observational
cohort substudy of
patients
included in
the
RECORD-AF
study

- 2,439
individuals with
new onset atrial
fibrillation
(within the past
year) from 21
countries

- The University of
Toronto Atrial
Fibrillation Severity
Scale (AFSS) was
calibrated to the
quantitative health
related quality of life
(HRQoL) in patients
with atrial fibrillation,
- Canadian
Cardiovascular Society
Severity in Atrial
Fibrillation (CCS-SAF)
scale utilized
- An increase of 1 class
in the CCS-SAF scale
corresponds to a 3-point
increase in AF symptom
severity score on the
AFSS

Study findings that
help answer the EBP
question
Retrospective - 10,087
- Symptom severity
analysis of
community
evaluated through
secondary
dwelling
application of the
data from the individuals
European Heart
ORBIT-AF
receiving
Rhythm Association
study
outpatient care
(EHRA) scale
(internal medicine, - Quality of life
cardiology,
correlated closely with
electrophysiology) symptom severity as
in the United States measured by the
with atrial
EHRA class
fibrillation
- Higher EHRA scores
and lower quality of
life were associated
with higher risk for
hospitalization
Evidence
Type

Sample, Sample
Size & Setting

50
- Risk for
selection
bias due to
evidence
type

Limitations
- Findings
may not be
transferrable
to
individuals
with limited
access to
care

Evidence
Level III;
High
Quality (A)

Evidence
Level &
Quality
Evidence
Level III;
High
Quality
(A)
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Article
#

Author
& Date

Evidence
Type

4

Wynn et
al.
(2014)

Research,
nonexperimental;
observational
sub-study

Article
#

Author &
Date

5

Nazli et al.,
2016

Study findings
that help answer
the EBP question
- 362 patients cared for at - Modification of
a designated heart
the European
rhythm/electrophysiology Heart Rhythm
clinic in England
Association
(mEHRA)
classification
- When compared
to the patientcompleted
instrument, the
Atrial Fibrillation
Effect on Quality
of Life (AFEQT),
the mEHRA is
effective at
categorizing
patient’s
symptoms
Sample, Sample Size &
Setting

Sample,
Sample Size &
Setting
Observational, - Men and
crosswomen with
sectional
one or more
study
episodes of
atrial fibrillation
- 135
individuals at a
cardiology
outpatient clinic
in a tertiary
hospital in
Turkey
Evidence
Type

Study findings that
help answer the EBP
question
- EHRA classification
and CCS-SAF scale both
used
- CCS-SAF applied to
quantify functional
impact of atrial
fibrillation
- EHRA applied to
assess functional impact
of atrial fibrillation

51
Evidence
Limitations
Level &
Quality
- Subjective
Evidence
findings
Level III;
- Limited
High
transferability Quality
to other
(A)
health care
providers

Limitations
- Nonspecific tool
utilized to
assess patient
quality of life

Evidence
Level &
Quality
Evidence
Level III;
Good
Quality
(A)
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Article
#
6

Article
#
7

Author &
Date
Vermond et
al., 2014

Author &
Date
King et al.,
2015

Sample,
Sample Size &
Setting
Retrospective, - 614 patients
correlational
initially
study; subrandomized to
study of
lenient or strict
patients
rate control
included in
- 558 patients
the RACE II
included in
study, which
analysis
was a quasi- Original
experimental RACE II setting:
study
29 centers in the
Netherlands
Evidence
Type

Evidence
Type

Sample, Sample
Size & Setting

Cohort
sub-study
from the
SMART
study

- Men (65%) and
women with an
average age of
71.1 years with
asymptomatic or
minimally
symptomatic
atrial fibrillation
- 48 individuals
enrolled through
the outpatient
Electrophysiology
Clinic at the
University of
North Carolina
Chapel Hill

Study findings that
help answer the EBP
question
- Symptom severity
measured by the
Toronto AF Severity
Scale (AFSS)
- Higher AFSS score
associated with
cardiovascular
outcomes

Study findings that help
answer the EBP
question
- Canadian Cardiovascular
Society Severity of Atrial
Fibrillation (CCS-SAF)
scale utilized to assess
symptom severity
- Individuals with limited
or no symptoms based on
implementation of the
CCS-SAF can benefit
from treatment of atrial
fibrillation

52

Limitations
- Title states
“symptom
severity is
associated”
- Post hoc
analysiscorrelation not
causation

Limitations
- Risk for
selection bias
- Noting
“significant
symptom
relief” when
treatment
may be from
a placebo
effect
(correlation
but not
causation)

Evidence
Level &
Quality
Evidence
Level III;
Good
Quality
(B)

Evidence
Level &
Quality
Evidence
Level III;
Good
Quality
(B)

IMPLEMENTING AN ATRIAL FIBRILLATION SCALE

Article
#
8

Article
#
9

Author &
Date
Chiang et
al., 2016

Author &
Date
Koci et al.,
2014

Sample,
Sample Size &
Setting
Retrospective - 11,198
analysis of
individuals with
secondary
atrial fibrillation
data from the - 831 sites in 26
Realise AF
countries
survey:
crosssectional,
observational
study
Evidence
Type

Study findings that help
answer the EBP
question
- European Heart
Rhythm Association
(EHRA) scale utilized for
assessing AF-related
symptom severity
- Slightly lower
proportion of individuals
with symptoms with a
rhythm strategy
compared to a rate
strategy for atrial
fibrillation (67.8% and
78.1%)

Study findings that
help answer the EBP
question
Qualitative - 224 Men (73.9%) - Implementation of a
and women
new classification
enrolled from five
scheme for symptom
different
severity and burden
electrophysiologists associated with atrial
at one center in
fibrillation (Atrial
Massachusetts
Fibrillation Symptom
and Burden, AFS/B)
- Following statistical
analysis, the AFS/B
correlated well with
health related quality of
life
Evidence
Type

Sample, Sample
Size & Setting

53

Evidence
Limitations Level &
Quality
- Discussion Evidence
of
Level III;
measurement Good
tools did not Quality
occur
(B)
- The
modified
European
Heart
Rhythm
Association
(mEHRA)
was not
utilized

Evidence
Level &
Quality
- Limited
Evidence
transferability Level III;
to other
Good
populations
Quality
- Claim for a (B)
new
classification
scheme, yet
further
research in
other
populations
has not been
fully
implemented
Limitations
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Article
#
10

Article
#
11

Author &
Date

Evidence
Type

European
Society of
Cardiology,
2016

Nonresearch:
clinical
practice
guideline

Author &
Date
Aliot, Botto,
Crijns, &
Kirchhof,
2013

Sample,
Sample Size
& Setting
Practice
guideline

Sample,
Evidence
Sample Size &
Type
Setting
NonLiterature
research; review
literature
review

Study findings that help
answer the EBP question
- Class I, Level C
recommendation for use of
the modified European
Heart Rhythm Association
(mEHRA) classification
scale

Study findings that help
answer the EBP question
- Atrial fibrillation specific
instruments can be used to
assess AF-related quality of
life
- Symptom based scales have
limitations including
comorbid conditions
- The CCS-SAF scale and the
EHRA classification score
may be helpful for assessing
impact of symptoms and
selecting treatment

54

Limitations
- No
consensus
across other
professional
organizations

Evidence
Level &
Quality
Evidence
Level IV;
High
Quality
(A)

Evidence
Level &
Quality
- Review,
Evidence
potential for Level V;
bias
High
Quality
(A)
Limitations
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Appendix C
Focused Search Strategy Table
Data Base
Search
1. PubMed

2. PubMed
3. PubMed
4. PubMed
5. PubMed

Key Words

Restrictions

Symptom scale AND atrial
fibrillation (118)

None

# articles
identified
5

# articles
relevant
2

Canadian Cardiovascular
Society AND atrial
fibrillation (62)
Canadian Cardiovascular
Society AND Severity of
atrial fibrillation (1)
Symptom instrument AND
cardiovascular (34)
Symptoms AND atrial
fibrillation (40,327)

None

3

0

None

1

Publication dates- within five years
(22)
Review (5,089); Date range 20162017 (625); Free full text (186)

1

0 (no
new
articles)
1

3

1
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Appendix D
Individual Evidence Summary Tool
EBP Question: What is the evidence to support use of the CCS-SAF scale?

Article
#

Author
& Date

Evidence
Type

1

Dorian et
al., 2006

Non-research;
Consensus

Article
#
2

Author &
Date
Dorian et
al., 2009

Sample, Sample
Size & Setting
- Consensus
statement

Findings that help
answer the EBP
question
- Use of a symptom
scale to assess the
severity of atrial
fibrillation
- The scale “attempts to
balance simplicity,
precision and
comprehensiveness with
simplicity to enhance
utility” (p. 384)
- Useful at assessing
quality of life and wellbeing (over-all impact
of AF, not just when in
it)
- Incorporates side
effects to
medications/impact on
quality of life

Findings that help
answer the EBP
question
Research,
- 484 patients
- CCS-SAF valid, but
nonevaluated in
not reliable
experimental cardiology clinics in - CCS-SAF provides
Vancouver, Calgary, an objective
London, Toronto,
assessment
and Montreal
- Captures all aspects
- 67% men
of atrial fibrillation
- 62% paroxysmal,
- Not limited to
38%
arrhythmia episodes
persistent/permanent
atrial fibrillation
Evidence
Type

Sample, Sample
Size & Setting

Limitations
- CCS-SAF
scale not
validated

Limitations
- Imperfectly
correlated to
SF-36 and
AFSS

Evidence
Level &
Quality
Evidence
Level IV;
High
Quality (A)

Evidence
Level &
Quality
Evidence
level III;
High
Quality
(A)
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Article
#

Author &
Date

3

Heidt et al.,
2016

Article
#

Author &
Date

4

Evidence
Type
Nonresearch;
Literature
review

Evidence
Type

Zimmerman Nonet al., 2016 research;
Literature
review

Sample, Sample
Size & Setting
- Literature review
(published between
1964-2016)

Sample, Sample
Size & Setting
- Literature review

Findings that help
answer the EBP
question
- Measuring
functional status for
symptom burden and
outcome measure
- CCS-SAF allows
identification of
patients into classes,
which can guide
treatment
- CCS-SAF intended
for routine clinical
use
- CCS-SAF assess
patient status and
serves as
communication for
functional
consequences

Findings that help
answer the EBP
question
- Comprehensive
analysis of
instruments used for
cardiovascular
populations
- The CCS-SAF scale
is valid, specific,
multi-dimensional,
and includes multiple
symptoms

57

Limitations
- Current
scales only
evaluate
symptoms at
one point in
time

Evidence
Level &
Quality
Evidence
level V;
Good
Quality
(B)

Evidence
Level &
Quality
- The CCSEvidence
SAF scale
level V;
lacks
High
reliability and Quality
responsiveness (A)
Limitations
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Appendix E
Canadian Cardiovascular Society
Severity of Atrial Fibrillation (SAF) Scale

Step 1 – Symptoms
Identify the presence of the following symptoms:
Palpitation
Dyspnea
Dizziness, presyncope, or syncope Chest pain
Weakness or fatigue
Step 2 – Association
Is AF, when present, associated with the above-listed symptoms (A-E)?
For example: Ascertain if any of the above symptoms are present during AF and likely caused by
AF (as opposed to some other cause).
Step 3 – Functionality
Determine if the symptoms associated with AF (or the treatment of AF) affect the
patient’s functionality (subjective quality of life).

Dorian et al., 2009
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CCS-SAF Class Definitions
Class 0
Asymptomatic with respect to AF
Class 1
Symptoms attributable to AF have minimal effect on patient’s general QOL.
•
•

minimal and/or infrequent symptoms, or
single episode of AF without syncope or heart failure

Class 2
Symptoms attributable to AF have a minor effect on patient’s general QOL.



mild awareness of symptoms in patients with persistent/permanent AF, or
rare episodes (e.g. less than a few per year) in patients with paroxysmal or intermittent
AF

Class 3
Symptoms attributable to AF have a moderate effect on patient’s general QOL.



moderate awareness of symptoms on most days in patients with
persistent/permanent AF, or
more common episodes (e.g. more than every few months) or more severe symptoms, or
both, in patients with paroxysmal or intermittent AF

Class 4
Symptoms attributable to AF have a severe effect on patient’s general QOL.





very unpleasant symptoms in patients with persistent/paroxysmal AF and/or
frequent and highly symptomatic episodes in patients with paroxysmal or intermittent AF
and/or
syncope thought to be due to AF and/or
congestive heart failure secondary to AF
Dorian et al., 2009
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Appendix G
ST CATHERINE UNIVERSITY
Information Regarding Proposed Project
You are invited to participate in the project, “Implementing an Atrial Fibrillation Symptom
Severity Scale to Assist with Management within the Subspecialty of Electrophysiology at the
Minneapolis Heart Institute.” The project will be implemented by Allison Helland Sill, a
doctoral nursing candidate at St. Catherine University in St. Paul, MN. The faculty advisor for
this project is Gwen Short, DNP, MPH, APRN, FNP through the St. Catherine University
Graduate Nursing program. The site advisor for this project is Jay Sengupta, MD.
The purpose of this project is to evaluate the impact implementation of the Canadian
Cardiovascular Society Severity of Atrial Fibrillation (CCS-SAF) scale has on developing a
treatment plan, evaluating response to treatment, and enhancing communication. This project is
important because symptom assessment is a cornerstone for managing atrial fibrillation (Koci et
al., 2014). Not only do symptoms give insight into the impact on quality of life, but they also
assist with monitoring response to treatment interventions (Koci et al., 2014). With the
increasing prevalence of individuals with atrial fibrillation, the need for adequate management
will continue to grow (Koci et al., 2014).
Below, you will find answers to the most commonly asked questions about participating in this
project.
Why have I been asked to participate?
Secondary to the high number of individuals with atrial fibrillation evaluated by the
electrophysiology group at the Minneapolis Heart Institute, this population will provide
beneficial feedback regarding the utility of the CCS-SAF scale.
If I decide to participate, what will I be asked to do?





Participate in a pre-implementation online survey and PowerPoint presentation
addressing the proposed project. This is estimated to take approximately 30 minutes.
Implement the CCS-SAF scale for all individuals evaluated in the clinic with a primary
visit diagnosis of atrial fibrillation (including paroxysmal, persistent, longstanding
persistent, and permanent). The time commitment for this will vary depending on the
population of individuals with atrial fibrillation. The estimated time to complete and
document the CCS-SAF numeric category should be less than two minutes per patient.
There will be a post-implementation survey after week eight. This is an online survey
and is estimated to take less than 10 minutes.

In total, this project will take approximately 184 minutes for providers at the Minneapolis, Edina,
Plymouth (WestHealth), and Chaska locations. There will be one initial session, which will
include a pre-implementation survey and PowerPoint presentation. The last session will include
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a 10 minute post-implementation survey. The remainder of the time will be spent completing
and documenting the CCS-SAF numeric category in the objective section of the clinic progress
note.
What if I decide I do not want to be involved?
Participation is completely voluntary. If you decide you do not want to participate, please do not
complete the pre-implementation survey. Completion of the pre-implementation survey implies
that you agree to participate. Your decision of whether to participate will have no negative or
positive impact on your relationship with St. Catherine University.
What are the risks of participation?
Risks include variability in scoring of the CCS-SAF scale. The scale is provider-administered
and thus open to subjectivity. This may result in some providers rating an individual’s severity
class higher than a colleague. A higher score indicates worsening impact on quality of life
(Dorian et al., 2009) and more aggressive management options with higher potential for
complications may ensue.
Another concern is breach of confidentiality when completing the online surveys. Given the
small population size, if de-identification is not completed properly, confidentiality could be
jeopardized.
What are the potential benefits of the project?
The direct benefit for participating in implementation of the CCS-SAF scale is providing an
enhanced ability to quickly identify severity of symptoms associated with atrial fibrillation
through a semi-quantitative scale. The goal of implementation is to have a consistent method for
assessing the impact atrial fibrillation has on an individual’s quality of life, assist with
developing a treatment plan, enhance communication, put in context the risks and benefits of
various medical and procedural options, and contribute to research (Aliot, Botto, Crijns, &
Kirchhof, 2014; Dorian et al., 2009).
Societal benefits include consistent symptom identification, which is as a cornerstone for the
management of atrial fibrillation (Koci et al., 2014). The long-term goal is to disseminate use to
providers within general cardiology, other cardiovascular subspecialties, and internal medicine.
This will assist in identifying when adjustments to the treatment regimen are needed or whether
to consider referral.
Will I receive any compensation for participating?
A gift card to Peace Coffee for the value of $25 will be granted at the end of the project in
recognition of participation.
What will you do with the information you get and how will you protect my privacy?
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The information that you provide will be de-identified and transferred to a numeric value. Only
the principal investigator and site advisor will have access to the key. This form will be entered
in an Excel document, which will require a password for access. The principal investigator will
finish analyzing the data by April of 2018, after which all original reports and identifying
information that can be linked back to you will be destroyed no later than June of 2018.
Any information that you provide will be kept confidential, which means that you will not be
identified or identifiable in any written reports or publications. If it becomes useful to disclose
any of your information, the principal investigator will seek your permission and tell you the
persons or agencies to whom the information will be furnished, the nature of the information to
be furnished, and the purpose of the disclosure; you will have the right to grant or deny
permission for this to happen. If you do not grant permission, the information will remain
confidential and will not be released.
Are there possible changes to the project once it gets started?
If during implementation of this project the principal investigator learns about new findings that
might influence your willingness to continue participating, you will be updated on these findings.
How can I get more information?
If you have any questions, feel free to contact the principal investigator at the following email
address, allison.sill@allina.com. If you have any additional questions later and would like to
talk to the faculty advisor, please contact Dr. Gwen Short at gsshort@stkate.edu. If you have
other questions or concerns regarding the project and would like to talk to someone other than
the investigator, you may also contact Dr. John Schmitt, Chair of the St. Catherine University
Institutional Review Board, at (651) 690-7739 or jsschmitt@stkate.edu.
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Post-implementation

SurveyMonkey

Q7 How could the scale be more easily integrated into the
documentation?
Answered: 6

Skipped: 2

#

RESPONSES

DATE

1

.phrase

2/7/2018 10:32 AM

2

Include with intake form filled out by new patients

2/5/2018 7:41 PM

3

I realize that I don't know the dot phrase or what to write.

1/31/2018 2:18 PM

4

dot phrase (for inpatient). more difficult for outpatients that are dicatated.

1/30/2018 12:36 PM

5

more automated into Epic

1/30/2018 11:32 AM

6

An enlarged copy posted in each workroom might help- to use as a reference. Mostly it's just a
learning/memory curve- I forgot to dictate it!!

1/30/2018 11:32 AM

1/1
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Post-implementation

SurveyMonkey

Q8 Comments or concerns regarding use of the CCS-SAF scale
Answered: 4

Skipped: 4

#

RESPONSES

DATE

1

more guidelines needed to connect scale with pathophysiology of disease

2/7/2018 10:32 AM

2

Same as above

1/31/2018 2:18 PM

3

Only used for a short period of time (so at most, one time for any given patient). Would be more
meaningful after longer follow-up periods (eg to assess trend in CCS-SAF scale after multiple
follow-up visits/interventions)

1/30/2018 12:36 PM

4

I think it's a great idea to have a common way to assess symptoms. The scale is fairly easy to use.
The toughest part is just remembering to do it.

1/30/2018 11:32 AM

1/1
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Appendix J
Qualifying Clinic Visit for Use of the CCS-SAF Scale
12/18/2017-1/26/2018
12/
18

12/
19

12/
20

12/
21

1/
2

1/
3

1/
4

1/
5

1/
8

1/
9

1/
10

1/
11

1/
12

1/
15

1/
16

1/
17

1/
18

1/
19

1/
22

1/
23

1/
24

1/
25

1/
26

Qualify

4

9

16

11

16

5

12

8

2

13

10

10

5

8

13

12

18

7

8

15

16

22

9

Completed

0

0

0

0

0

0

1

6

0

4

0

5

0

0

0

0

0

0

0

0

0

7

0

Red = CCS-SAF incorporated into notes section on schedule

